Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Review examined trials comparing aromatase inhibitors for neoadjuvant chemotherapy
February 23rd, 2006
Clinical trials comparing aromatase inhibitors for neoadjuvant chemotherapy were recently reviewed. "Tamoxifen therapy has been the standard of care for the adjuvant treatment of estrogen receptor-positive early-stage breast cancer for many years and was the first hormonal treatment for postmenopausal women with advanced or metastatic disease. The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole offer new treatment options, although their efficacy has not been compared directly in randomized, double-blind, controlled trials in any breast cancer treatment setting," stated J. Berry from the MacNeal Cancer Center in Berwyn,...
Source: Women's Health Weekly (2006-02-23)
|
